Conference call interim report
Invitation to attend Vitrolife’s conference call regarding presentation of the interim report for the period January - March 2013. The presentation will be held in English.
ay, April 19, 2013 at 10 a.m. CET.
Registration can preferably be done in advance under the following link:
or shortly before the conference starts on:
Sweden dial in number: +46 (0)8 5052 0110
UK dial in number: +44 (0)20 7162 0077
Conference name: Vitrolife, conference ID: 931066
Thomas Axelsson, CEO
Mikael Engblom, CFO
The press release for Vitrolife’s interim report will be released at 08:30 a.m. CET on Friday, April 19.
Before the conference call, slides will be available at the company web page , www.vitrolife.com/en/Corporate/ .
A recorded version of the conference call will be available for seven days on number
+46 (0)8 505 203 33 (Sweden) or +44 (0)20 7031 4064 (UK), access code 931066 .
Gothenburg, April 10, 2013
VITROLIFE AB (publ)
For further information, please contact:
Mikael Engblom, CFO, 46 31 721 80 14
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife is a global medical device Group. Vitrolife Fertility product area develops, produces and markets products for the treatment of human infertility. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes
Vitrolife has approximately 230 employees and the company's products are sold in almost 100 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan and Hungary. The Vitrolife share is listed on NASDAQ OMX Stockholm , Small Cap.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: firstname.lastname@example.org. Website: www.vitrolife.com/